Skip to content
drillr.ai

DYN

Dyne Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$23.45-1.22%

Price as of Jul 20, 2026

DYN news

Dyne Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

    - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen once every 4 weeks resulted in a robust and statistically significant increase in dystrophin production with functional improvement observed across multiple clinical endpoints and a favorable safety profile(1) - WALTHAM, Mass., July 20, 2026

    Globe Newswire ·

  2. Dyne Therapeutics Appoints Barry Greene to Board of Directors

    WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=ghLzGp3fVpp-3K8wzFF6a1tI8G2HGDOv8sQNMyTq0buzZG25daB1_VW-CWdJweqVkVAC1F-kT0TrCzIb0BIr76zmI_zLwLxMpVOxiEpgCas=) (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of b

    Globe Newswire ·

  3. Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc (https://www.globenewswire.com/Tracker?data=2mn7GbeaZ7bvP6OPcjKBJ33SVcEUyovmUgxD3Szt6eDbsbi-gbPmE_i0YZADyrsXn_xH0jRoTov-nV1w6S96jgttB3ehHWZCacWmD-0ouFQ=). (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 6 newly hired employees. The awards were made as an induc

    Globe Newswire ·

  4. Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

    - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -  WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=jk1iSJ12Bfsu6dx8UE5NkYP0yH521AyVm7zdT7lkOylsheT3l0Eps5HhgygAWPjwH9SCJFooqFtXSdtVxqmlLIPzZ1eEcTPxTTR1Sftvuns=) (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the comp

    Globe Newswire ·

  5. Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

    - 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function - - FORZETTO trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications - WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc (https://www.glob

    Globe Newswire ·

  6. Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

    - Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA conference - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 on track for Q2 2026; global confirmatory Phase 3 HARMONIA trial initiated -

    Globe Newswire ·

  7. Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

    - Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=A-ZMWfmE2r0h1erg-F7rvi63Ub7F1rj0_zrhjsokK8WzhgdWdqo7R6KiAOqQm3-rnpu_e467k6Mz8898H2dr3A4l-SMKF6BttLldsZjiaWc=) (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular dis

    Globe Newswire ·

  8. Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

    - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes - - HARMONIA trial design and protocol aligned with FDA; trial intended to serve as confirmatory tri

    Globe Newswire ·

  9. Dyne Therapeutics to Participate in Upcoming Investor Conferences

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNX7lBxpH&default-theme=true WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc (https://www.globenewswire.com/Tracker?data=d_kUA64jFMO2IwSI0u_gi_VZ_Faa16fjbc5E1u2w4U42HK6lZnUAD7S4XpmSNiPI03rYLa4UfIalvUpBPv4dCmK2-T6L9rHidQtCUJ7T93c=). (Nasdaq: DYN), a clinical-stage company focused on delivering functional im

    Globe Newswire ·